Assessment Of The Atopic Dermatitis Industry 2026-2036: Persistent Diagnostic Gaps Highlight Major Unmet Needs
The atopic dermatitis market across the seven major markets (7MM)-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-is expected to expand significantly through 2036. The market was valued at approximately USD 13 billion in 2025 and is projected to reach nearly USD 28 billion by 2036, representing a compound annual growth rate of approximately 7% from 2026 to 2036.
The report provides a comprehensive assessment of historical and forecast epidemiology, treatment practices, market size, therapy uptake, competitive dynamics, pricing, reimbursement, and unmet medical needs across the 7MM. The analysis includes market forecasts from 2022 to 2036 and evaluates the commercial potential of approved and emerging atopic dermatitis therapies.
Key Atopic Dermatitis Market Insights
- The 7MM atopic dermatitis market was valued at approximately USD 13 billion in 2025 and is forecast to approach USD 28 billion by 2036. The United States accounted for the largest regional market, generating approximately USD 9 billion in 2025. Approximately 73.2 million prevalent atopic dermatitis cases were recorded across the 7MM in 2025. The United States accounted for approximately 33.1 million diagnosed prevalent cases in 2025. Most diagnosed cases are mild to moderate, although moderate-to-severe disease creates a disproportionate clinical and economic burden. Atopic dermatitis is more prevalent among females, while children represent a substantial proportion of the affected population. Approximately 25% of cases may remain undiagnosed or misdiagnosed, contributing to treatment delays, disease progression, and reduced quality of life.
Evolving Atopic Dermatitis Treatment Landscape
Atopic dermatitis treatment is determined by disease severity, affected body surface area, previous response, age, comorbidities, and patient preferences. Foundational management includes emollients, topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 inhibitors, and other nonsteroidal topical therapies. Phototherapy and systemic treatments may be considered for patients with widespread, refractory, or moderate-to-severe disease.
The 2017 approval of DUPIXENT (dupilumab) marked a major transition toward targeted systemic treatment. Its subsequent expansion into adolescent and pediatric populations established the therapy as a leading option for patients whose disease is inadequately controlled with topical prescriptions or for whom those treatments are unsuitable. DUPIXENT generated the highest estimated atopic dermatitis therapy revenue in the United States in 2025.
Competition has intensified with the introduction of targeted biologics, oral Janus kinase inhibitors, and newer topical agents. Approved therapies include RINVOQ (upadacitinib), CIBINQO (abrocitinib), ADBRY/ADTRALZA (tralokinumab), EBGLYSS (lebrikizumab), VTAMA (tapinarof), and other regionally available products. RINVOQ has achieved strong market traction, supported by clinical data demonstrating rapid itch relief and high levels of skin clearance in eligible patients.
Biologics and JAK inhibitors are expected to remain central to atopic dermatitis market growth. Biologics targeting interleukin pathways offer durable disease control, while oral JAK inhibitors provide rapid efficacy and an alternative to injectable treatment. Safety monitoring, boxed warnings, reimbursement requirements, and long-term evidence will continue to influence prescribing and therapy sequencing.
Pipeline and Competitive Landscape
The atopic dermatitis pipeline includes biologics, oral small molecules, topical agents, and therapies targeting emerging immune pathways. Amlitelimab, an OX40L-targeting monoclonal antibody, remains among the closely watched late-stage candidates for moderate-to-severe atopic dermatitis. Other development programs are evaluating differentiated approaches to inflammation, pruritus, and long-term disease control. Kyowa Kirin announced on March 3, 2026, that all clinical trials of rocatinlimab would be terminated.
Leading companies active in the atopic dermatitis therapeutics market include Sanofi, Regeneron Pharmaceuticals, AbbVie, Eli Lilly and Company, Pfizer, LEO Pharma, Galderma, Roche, Chugai Pharmaceutical, Maruho, Otsuka Pharmaceutical, Incyte, and Torii Pharmaceutical.
Recent industry developments include:
- In March 2026, Sanofi presented new Phase III amlitelimab findings at the American Academy of Dermatology Annual Meeting. In March 2026, Eli Lilly reported positive Phase III ADorable-1 results for lebrikizumab in pediatric patients aged six months and older, supporting planned regulatory submissions for label expansion. In September 2025, the US Food and Drug Administration approved OPZELURA (ruxolitinib) cream for children aged 2-11 years with atopic dermatitis, expanding pediatric access to topical JAK inhibition.
Market Growth Drivers and Opportunities
Growth in the atopic dermatitis market is supported by rising diagnosed prevalence, improved disease awareness, broader access to dermatology services, expanding pediatric indications, and increasing use of targeted therapies. Greater recognition of the effects of persistent itching, sleep disruption, mental health burden, and impaired daily functioning is also strengthening demand for sustained disease control.
Significant opportunities remain for therapies that offer long-term safety, convenient administration, rapid symptom improvement, durable skin clearance, and effectiveness across age groups. Pediatric biologics and nonsteroidal topical treatments represent particularly important areas of development. Emerging therapies may also gain traction among patients with persistent pruritus or inadequate responses to existing biologics and systemic treatments.
Key unmet needs include delayed or inaccurate diagnosis, limited personalized treatment strategies, variable access to specialists, insufficient age-specific options, high treatment costs, and inconsistent reimbursement. Addressing these barriers will be critical to improving adherence, expanding market access, and reducing the long-term patient burden.
Report Coverage and Strategic Value
The report combines epidemiology-based forecasting with therapy-level market analysis to assess patient populations, addressable markets, drug adoption, peak patient share, pricing trends, and competitive positioning. It also examines clinical trial activity, regulatory developments, patents, collaborations, treatment guidelines, and product profiles for marketed and pipeline therapies.
Primary research incorporates insights from key opinion leaders and subject-matter experts across the 7MM. These perspectives support analysis of prescribing behavior, treatment switching, patient adherence, market access, clinical development priorities, and real-world treatment patterns. SWOT and conjoint analyses further compare therapies based on efficacy, safety, administration route, dosing frequency, market-entry timing, probability of success, and addressable patient population.
The findings are designed to support pharmaceutical companies, investors, healthcare organizations, and other stakeholders in evaluating atopic dermatitis market opportunities, prioritizing pipeline assets, developing commercialization strategies, and anticipating changes in the treatment landscape through 2036.
A selection of companies mentioned in this report includes, but is not limited to:
- Organon/ Torii Pharmaceutical Roche/Eli Lilly and Company/ Almirall Chugai Pharmaceutical/ Galderma/ Maruho AbbVie Pfizer LEO Pharma Otsuka Pharmaceutical Incyte Corporation Torii Pharmaceutical Sanofi Regeneron Pharmaceuticals
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment